Table 2 Summary of significantly upregulated immune cells phenotypes

Activated myeloid cells in TBLN MNCs [CD3⁻CD172⁺CXCL10⁺]

**p < 0.01

IFNγ⁺ Effector memory T-helper/Memory cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻CD27⁻IFNγ⁺]

*p < 0.05

Total IL-17A⁺ T-helper/Memory cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻IL-17A⁺]

**p < 0.01

IL-17A⁺ Central memory T-helper/Memory Cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻CD27⁺IL-17A⁺]

**p < 0.01

IL-17A⁺ Effector memory T-helper/Memory cells in PBMCs [CD3⁺CD4⁺CD8α⁺CD8β⁻CD27⁻IL-17A⁺]

**p < 0.01

Total IL-17A⁺ CTLs in PBMCs [CD3⁺CD4⁻CD8α⁺CD8β⁺IL-17A⁺]

^♯p < 0.05

IL-17A⁺ Early effector CTLs in PBMCs [CD3⁺CD4⁻CD8α⁺CD8β⁺CD27⁺IL-17A⁺]

^♯p < 0.05

Total IL-17A⁺ CTLs in TBLN MNCs [CD3⁺CD4⁻CD8α⁺CD8β⁺IL-17A⁺]

^##***p < 0.01

IL-17A⁺ Late effector CTLs in PBMCs [CD3⁺CD4⁻CD8α⁺CD8β⁺CD27⁻IL-17A⁺]

***p < 0.001